Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer

Exclusion Criteria

• •Previous treatment with oxaliplatin, irinotecan or fluorouracil
• •Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.
• •With distant metastasis
• •Cardiovascular disease that would preclude study treatment or follow-up; New York Heart Association class III or IV heart disease; active ischemic heart disease; myocardial infarction within the past 6 months; symptomatic arrhythmia uncontrolled hypertension. Unexplained syncope occurred within 3 months
• •Digestive system diseases that would preclude study treatment or follow-up within the past 6 months
• •Gastric ulcers or duodenal ulcers for the treatment of resistance;
• •3 or 4 grade gastrointestinal bleeding / bleeding;
• •Gastrointestinal perforation / fistula;
• •abdominal abscess;
• •Infectious or inflammatory bowel disease
• •HIV infection and/or active hepatitis B virus infection
• •Pregnant or lactating women. Fertile patients must use effective contraception
• •Any serious acute or chronic disease that can not be involved in the study or to influence the interpretation of the results of the study
• •Other intervention clinical trials were combined at the same time.
• •Nerve or mental abnormality affecting cognitive ability
• •Other malignancy except effectively treated squamous cell or basal cell skin cancer,
• •Other situations that the researchers think should be excluded